At Revalesio, we are dedicated to developing and delivering safe and effective treatments for people suffering from acute and chronic conditions. To achieve this, we collaborate internationally with scientists, physicians, patients, and health authorities to conduct comprehensive clinical trials.
We understand that some patients who do not qualify for clinical trial participation may seek access to investigational therapies before they receive regulatory approval. This type of access is often referred to as “expanded access,” “early access,” “compassionate use,” or a “named patient program.”
While we empathize with the urgent need for treatment options, RNS60 can only be accessed by new patients via participation in a clinical trial.
We believe this approach best ensures the timely development of safe and effective treatments for the largest possible number of patients.
